Anyone have TIRAD 4 findings ultrasound and biopsy pathology Bethesda III had radio frequency ablation if you're on a GLP-1 like semaglutide or tirzepatide

Understanding TIRADS 4 and Bethesda III Results

When an ultrasound shows a TIRADS 4 thyroid nodule, it carries a 5-20% risk of malignancy, prompting further evaluation. A fine-needle aspiration biopsy returning Bethesda III (atypia of undetermined significance) means the cells look suspicious but aren't clearly cancerous—about 10-30% prove malignant on further testing. In my experience helping patients with obesity, diabetes, and hormonal shifts, these findings often surface during routine care while pursuing sustainable weight loss. Many in their late 40s and early 50s face joint pain that limits exercise and conflicting nutrition advice that overwhelms. My methodology in The CFP Weight Loss Protocol emphasizes addressing root metabolic and hormonal barriers before adding medications.

Radiofrequency Ablation for Thyroid Nodules

Radiofrequency ablation (RFA) offers a minimally invasive option to shrink benign or indeterminate nodules without surgery. Studies show 50-80% volume reduction within 6-12 months, with low complication rates under 3%. For patients managing blood pressure and blood sugar alongside weight, RFA avoids anesthesia risks tied to traditional surgery. Post-RFA, we monitor with serial ultrasounds every 6 months initially. In my protocol, I integrate this with gradual lifestyle shifts—focusing on anti-inflammatory meals that take under 20 minutes to prepare—to support recovery without adding stress.

GLP-1 Medications Like Semaglutide and Tirzepatide: Thyroid Considerations

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) deliver 15-20% average weight loss in clinical trials, improving insulin sensitivity and reducing joint strain that makes movement feel impossible. However, rodent studies raised concerns about thyroid C-cell tumors, though human data from millions of users show no clear causal link to thyroid cancer. The FDA label advises against use in those with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. For someone with treated TIRADS 4 and Bethesda III, I recommend endocrinologist clearance before starting. In The CFP Weight Loss Protocol, we start at the lowest dose (0.25 mg semaglutide weekly), titrate slowly over 8-12 weeks, and pair with 1.6g protein per kg ideal body weight to preserve muscle. Track calcitonin levels and nodule size every 6 months. Insurance barriers are real—many middle-income patients qualify for compounded versions or patient assistance while building habits that last beyond the medication.

Practical Steps for Safe Progress

Begin with a full thyroid panel, neck ultrasound, and endocrinology consult. Combine RFA follow-up with my simple plate method: half non-starchy vegetables, quarter lean protein, quarter complex carbs. Add 10-minute daily walks to ease joint pain without gym intimidation. Most see blood pressure drop 5-10 mmHg and A1C improvements within 3 months. Avoid drastic calorie cuts that worsen hormonal imbalances common in perimenopause. If you've failed diets before, focus on consistency over perfection—my patients report renewed confidence without embarrassment. Always coordinate care between your weight loss clinician and thyroid specialist for personalized monitoring.